RT Journal Article
T1 SARS-CoV-2: what it is, how it acts, and how it manifests in imaging studies.
T2 SARS-CoV-2: cómo es, cómo actúa y cómo se expresa en la imagen.
A1 Fernández-Pérez, G C
A1 Oñate Miranda, M
A1 Fernández-Rodríguez, P
A1 Velasco Casares, M
A1 Corral de la Calle, M
A1 Franco López, Á
A1 Díez Blanco, M
A1 Cuchat, J M Oñate
K1 COVID-19
K1 PET/TC
K1 Percusión pulmonar PBV
K1 SARS-2
K1 SARS-CoV-2
K1 TC alta resolución
K1 TC doble energía
K1 dual-energy CT
K1 high-resolution CT
K1 lung perfusion blood volume
AB COVID-19 is a disease with many clinical, biochemical, and radiological signs that has a predilection for the lungs, probably because of the high number of ACE-2 receptors in this organ. The infection of cells activates proinflammatory substances, causing diffuse alveolar damage, which is the histopathological basis of ARDS. The exudative phase would manifest as ground-glass opacities and consolidation, and the proliferative phase would manifest as a tendency toward a more linear morphology. Both CT and PET/CT findings support the inflammatory character of the lung lesions in the initial phase of the disease and in patients with mild-moderate disease. Severe cases have pulmonary hypoperfusion that is likely due to abnormal alveolar ventilation and perfusion. On the other hand, a prothrombotic state increases the risk of thromboembolic disease through the activation of coagulation and platelet pathways with the production of fibrin degradation products (D-dimer) and consumption of platelets.
YR 2020
FD 2020-11-17
LK http://hdl.handle.net/10668/16781
UL http://hdl.handle.net/10668/16781
LA en
LA es
DS RISalud
RD May 11, 2025